ArticleFrontiers in oncology2025
Benefit-risk evaluation of Fuzheng Yiliu Decoction combined with chemotherapy for treating non-small cell lung cancer using multicriteria decision analysis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study uses multi-criteria decision analysis (MCDA) to evaluate the benefits and risks of combining Fuzheng Yiliu Decoction with chemotherapy in treating non-small cell lung cancer (NSCLC). The aim is to improve clinical outcomes for NSCLC patients by integrating traditional Chinese medicine with conventional chemotherapy. Methods: A comprehensive literature search was conducted in PubMed, Web of Science, China National Knowledge Infrastructure (CNKI), China Biology Medicine Disc (CBM), Wanfang Databases, and China Science and Technology Journal Database (VIP Databases) to identify relevant studies on Fuzheng Yiliu Decoction combined with chemotherapy for NSCLC. Meta-analysis using RevMan 5.3 was performed to compare the effect sizes of the two treatment regimens. A MCDA model was developed to construct a value tree based on benefit-risk indicators. The benefit value, risk value, and benefit-risk ratio for both treatments were calculated using Hiview 3.2 software, followed by sensitivity analysis to assess result robustness. Monte Carlo simulations were performed using Oracle Crystal Ball 11.1 software to optimize the evaluation outcomes. Results: The literature search identified 6 randomized controlled trials (RCTs) comparing chemotherapy alone with chemotherapy combined with Fuzheng Yiliu Decoction. The MCDA model showed that the combination therapy had significantly higher benefit values (72) compared to chemotherapy alone (29). The risk value for combination therapy (56) was slightly higher than that of chemotherapy alone (24), but the overall benefit-risk value for combination therapy (68) was notably greater than chemotherapy alone (27). Monte Carlo simulations revealed a difference in total efficacy-risk values between the two treatments of 41 (95% CI: -16.59, 38.73). The probability that the combination therapy's benefit-risk value exceeds that of chemotherapy alone was 81.83%. Discussion: These findings suggest that combining Fuzheng Yiliu Decoction with chemotherapy improves therapeutic efficacy and reduces chemotherapy's adverse side effects, offering a promising treatment strategy for NSCLC. This study provides valuable insights into enhancing treatment strategies and clinical decision-making in managing NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.